Deep Dive #15: Adeno-Associated Virus (AAV) Delivery
BIOS: Nucleus of Life Science Innovation 🚀
JOBS
BIOS Talent: Find Jobs @ Breakout TechBio Startups — Search Jobs 🚀
Post Jobs: Add Your Startup to BIOS Talent — Post Now 🎉
Students: Join Alix Ventures Fellowship — Join Now 🧬
BIOS Contributor: Share Your Thought Leadership — Join Now🔬
CONTENT & COMMUNITY
BIOS Daily: Join 25K+ Subscribers Following TechBio — Sign Up 🔥
BIOS Insider: Premium TechBio Thought Leadership — Sign Up ✨
BIOS Commons: World’s Largest #TechBio Community — Join Now 🎉
INVEST
BIOS Angels: 1st TechBio Angel Investing Syndicate — Join Now 🌟
Alix Limited: Invest in Breakout TechBio Startups — Learn More 🧠
By:
Alix Ventures: Supporting Early Stage Life Science Startups Engineering Biology to Drive Radical Advances in Human Health
Overview
25 years ago, Adeno Associated Virus (AAV) had almost no industry specific interest - labeled as purely “academic” research. Fast forward to present day & the landscape is busier than ever. Emerging AAV based companies are prevalent all throughout the world from emerging startups all the way to large scale pharmaceutical companies - with 2021 serving as a breakout year where we saw VC investment rocket up 39% in the category.
The AAV Vector-Based Gene Therapy market size is anticipated to grow exponentially over the coming years with the increase in the approval of a growing number of gene therapies, ability to treat a broad array of conditions, the promise of convenient one-time dosing, & the potential for curative treatment options.